• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

    5/31/23 8:39:27 AM ET
    $ACON
    $ACRX
    $AMBA
    $ASPI
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • VIQ Solutions Inc. (NASDAQ:VQS) shares rose 66.8% to $0.3887 in pre-market trading.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) shares surged 59% to $0.4307 in pre-market trading after dropping 14% on Tuesday.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) shares rose 50% to $0.2009 in pre-market trading. Vistagen will present fasedienol safety and exploratory efficacy data from Phase 3 Open-label social anxiety disorder study at the American Society for Clinical Psychopharmacology Annual Meeting.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) gained 27.3% to $1.77 in pre-market trading after declining around 5% on Tuesday.
    • LL Flooring Holdings, Inc. (NYSE:LL) shares gained 19.1% to $4.93 in pre-market trading. LL Flooring confirmed the receipt of $5.76 per share unsolicited, non-binding proposal from Cabinets To Go, a subsidiary of F9 Brands.
    • Edgio, Inc. (NASDAQ:EGIO) rose 14.1% to $0.5650 in pre-market trading.
    • Mobilicom Limited (NASDAQ:MOB) rose 13.2% to $1.54 in pre-market trading after gaining 7% on Tuesday. Mobilicom recently received a purchase order for its end-to-end product solution that will be installed into autonomous and remote-controlled electric vehicles for homeland security and defense.
    • Netcapital Inc. (NASDAQ:NCPL) gained 10.1% to $1.42 in pre-market trading after declining 7% on Tuesday. The company recently reported closing of registered direct offering.
    • Micromobility.com Inc. (NASDAQ:MCOM) shares climbed 10.1% to $0.40 in pre-market trading after dropping around 6% on Tuesday. The company recently posted a rise in quarterly sales.
    • Recruiter.com Group, Inc. (NASDAQ:RCRT) shares gained 9.6% to $0.2465 in pre-market trading after gaining 4% on Tuesday. Recruiter.com, last month, announced the launch of Candidate Pitch, an AI web application.

    Losers

    • Belite Bio, Inc (NASDAQ:BLTE) fell 37.2% to $14.76 in pre-market after the company reported pricing of $30 million underwritten public offering of American Depositary Shares and warrants.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares dropped 31.6% to $0.0928 in pre-market trading. Biodexa Pharmaceuticals recently reported closing of $3.32 million registered direct offering.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares dropped 26.1% to $0.5675 in pre-market trading.
    • QualTek Services Inc (NASDAQ:QTEK) fell 19.3% to $0.12 in pre-market trading after jumping 96% on Tuesday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
    • Wejo Group Ltd (NASDAQ:WEJO) fell 19.2% to $0.10 in pre-market trading. Wejo Group shares dipped 57% on Tuesday after the company said it is evaluating whether to file ancillary insolvency proceedings for the company and other units in other jurisdictions, including the US.
    • AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) fell 18.6% to $0.80 in pre-market trading after declining 11% on Tuesday. AcelRx Pharmaceuticals recently posted a narrower-than-expected quarterly loss.
    • Ambarella Inc (NASDAQ:AMBA) fell 17.9% to $67.30 in pre-market trading after the company issued a weak second-quarter forecast.
    • ASP Isotopes Inc (NASDAQ:ASPI) shares fell 13.5% to $0.30 in pre-market trading after gaining 6% on Tuesday.
    • UTime Ltd (NASDAQ:UTME) fell 12.7% to $1.31 in pre-market trading after jumping 30% on Tuesday.
    • Aclarion Inc (NASDAQ:ACON) fell 10.5% to $0.94 in pre-market trading. Aclarion shares jumped 78% on Tuesday after the company announced a commercial agreement with the London Clinic and London Spine Clinic.

     

    Now Read This: Investor Optimism Declines After Dow Settles Lower

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ACRX
    $AMBA
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    SEC Filings

    View All

    SEC Form 8-K filed by Ambarella Inc.

    8-K - AMBARELLA INC (0001280263) (Filer)

    2/27/26 5:13:15 PM ET
    $AMBA
    Semiconductors
    Technology

    Ambarella Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - AMBARELLA INC (0001280263) (Filer)

    2/26/26 4:24:13 PM ET
    $AMBA
    Semiconductors
    Technology

    Amendment: SEC Form S-1/A filed by Netcapital Inc.

    S-1/A - Netcapital Inc. (0001414767) (Filer)

    2/24/26 4:40:35 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ambarella, Inc. Announces Fourth Quarter and Fiscal Year 2026 Financial Results

    SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2026 financial results for the period ended January 31, 2026. Revenue for the fourth quarter of fiscal 2026 was $100.9 million, up 20.1% from $84.0 million in the same period in fiscal 2025. For the fiscal year ended January 31, 2026, revenue was $390.7 million, up 37.2% from $284.9 million for the fiscal year ended January 31, 2025.Gross margin under U.S. generally accepted accounting principles (GAAP) for the fourth quarter of fiscal 2026 was 58.4%, compared with 60.0% for the same period in fiscal 2025. For the fisca

    2/26/26 4:05:00 PM ET
    $AMBA
    Semiconductors
    Technology

    Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 2, 2026, at 3:50 p.m. Eastern Time. A replay of the webcast will be archived and available following the event through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical com

    2/25/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream

    MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi

    2/25/26 7:00:00 AM ET
    $AEMD
    $ASPI
    $CLNN
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Senior VP, Systems & GM, Asia Ju Chi-Hong sold $558,136 worth of Ordinary Shares (7,945 units at $70.25), decreasing direct ownership by 5% to 149,587 units (SEC Form 4)

    4/A - AMBARELLA INC (0001280263) (Issuer)

    1/23/26 6:05:29 PM ET
    $AMBA
    Semiconductors
    Technology

    Senior VP, Systems & GM, Asia Ju Chi-Hong sold $584,105 worth of Ordinary Shares (7,728 units at $75.58), decreasing direct ownership by 5% to 146,039 units (SEC Form 4)

    4 - AMBARELLA INC (0001280263) (Issuer)

    1/7/26 5:02:14 PM ET
    $AMBA
    Semiconductors
    Technology

    Chief Operating Officer Prince Joshua S. was granted 4,386 shares, increasing direct ownership by 40% to 15,249 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    1/5/26 8:51:53 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Financials

    Live finance-specific insights

    View All

    Ambarella, Inc. Announces Fourth Quarter and Fiscal Year 2026 Financial Results

    SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2026 financial results for the period ended January 31, 2026. Revenue for the fourth quarter of fiscal 2026 was $100.9 million, up 20.1% from $84.0 million in the same period in fiscal 2025. For the fiscal year ended January 31, 2026, revenue was $390.7 million, up 37.2% from $284.9 million for the fiscal year ended January 31, 2025.Gross margin under U.S. generally accepted accounting principles (GAAP) for the fourth quarter of fiscal 2026 was 58.4%, compared with 60.0% for the same period in fiscal 2025. For the fisca

    2/26/26 4:05:00 PM ET
    $AMBA
    Semiconductors
    Technology

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ambarella Announces Fourth Quarter and Fiscal Year 2026 Earnings Conference Call to be Held February 26, 2026

    SANTA CLARA, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced it will hold its fourth quarter and fiscal year 2026 earnings conference call on Thursday, February 26, 2026 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day. Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the d

    2/5/26 8:00:00 PM ET
    $AMBA
    Semiconductors
    Technology

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care